SCHEMBL25317185

SCHEMBL25317185

CCCCCCCCC(CCCCCC)C(=O)N(C)CCCCCCCCN(C)CCCCCCCCN(C)C(=O)C(CCCCCC)CCCCCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.46
S1PR1 P21453 1/20 0.46
S1PR3 Q99500 1/20 0.46
S1PR5 Q9H228 1/20 0.46
CA2 P00918 1/20 0.44
GGPS1 O95749 4/20 0.44
KDM5A P29375 5/20 0.43
KDM4C Q9H3R0 5/20 0.43
PHF8 Q9UPP1 2/20 0.43
KDM5C P41229 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
GRIK1 P39086 1/20 0.40
GRIK2 Q13002 1/20 0.40
KDM4A O75164 1/20 0.40
FDPS P14324 1/20 0.39
AGTR1 P30556 1/20 0.39
OPRM1 P35372 1/20 0.39
PDE3A Q14432 1/20 0.39
GPR84 Q9NQS5 3/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29180336 0.95 CA2 (0.48) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL23928465 0.91 CA2 (0.46) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25698920 0.88 CA2 (0.47) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25319726 0.88 LMNA (0.43) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL24764590 0.88 CA2 (0.47) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL13003586 0.87 CA2 (0.48) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL23928464 0.87 EPHX2 (0.41) CA2GGPS1GPR84FFAR1EPHX2
SCHEMBL25914044 0.86 S1PR2 (0.46) S1PR2S1PR1S1PR3S1PR5CA2
SCHEMBL25414195 0.86 S1PR2 (0.46) S1PR2S1PR1S1PR3S1PR5CA2
SCHEMBL24340301 0.84 CA2 (0.46) CA2GRIK1GRIK2GPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS ACUITAS THERAPEUTICS INC (CA) 2025-06-12 US disclosed
US-12129223-B2 Lipids for use in lipid nanoparticle formulations Acuitas Therapeutics, Inc. (CA) 2024-10-29 US disclosed
EP-4448485-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 S1PR2 181/4885S1PR1 169/4885S1PR3 114/4885
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 S1PR2 181/4885S1PR1 169/4885S1PR3 114/4885
US-12129223-B2 Lipids for use in lipid nanoparticle formulations PHOSPHO1, SGMS1, NPC1 S1PR2 181/4885S1PR1 169/4885S1PR3 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.